Reactivating key proteins to treat HPV-related head and neck cancer
Dual p300 and p53 reactivation in HPV+ head and neck cancer
This study is testing a new treatment for people with HPV-positive throat cancer that aims to boost the body’s natural defenses against the cancer by using a special compound called OHM1, which could make current treatments work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11136485 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment approach for patients with HPV-positive oropharyngeal cancer (OPC) by targeting the interaction between HPV oncogene E6 and two important proteins, p53 and p300. The study aims to disrupt this interaction using a lead compound called OHM1, which has shown promise in laboratory models by reactivating p53 and p300, leading to anti-tumor responses. Patients may benefit from this innovative therapy as it could enhance the effectiveness of existing treatments like cisplatin. The research will explore the mechanisms behind this dual reactivation to better understand how to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with HPV-positive oropharyngeal cancer who are seeking new treatment options.
Not a fit: Patients with HPV-negative head and neck cancers or those who do not have access to the specific treatment being tested may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel therapeutic strategy that significantly improves treatment outcomes for patients with HPV-positive head and neck cancer.
How similar studies have performed: Other research has shown promising results in targeting similar pathways in cancer treatment, indicating that this approach could be a meaningful advancement.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Pan, Quintin — Case Western Reserve University
- Study coordinator: Pan, Quintin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.